| Year |
Citation |
Score |
| 2021 |
Thoreen CC. Split-personality inhibitors. Nature Chemical Biology. PMID 34168366 DOI: 10.1038/s41589-021-00820-8 |
0.367 |
|
| 2020 |
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. Correction: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of Biological Chemistry. 295: 2886. PMID 32111721 DOI: 10.1074/Jbc.Aac120.012837 |
0.65 |
|
| 2017 |
Thoreen CC. The molecular basis of mTORC1-regulated translation. Biochemical Society Transactions. 45: 213-221. PMID 28202675 DOI: 10.1042/BST20160072 |
0.324 |
|
| 2016 |
Muranen T, Selfors LM, Hwang J, Gallegos LL, Coloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS. ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Research. PMID 27913436 DOI: 10.1158/0008-5472.Can-16-0155 |
0.513 |
|
| 2015 |
Son S, Stevens MM, Chao HX, Thoreen C, Hosios AM, Schweitzer LD, Weng Y, Wood K, Sabatini D, Vander Heiden MG, Manalis S. Cooperative nutrient accumulation sustains growth of mammalian cells. Scientific Reports. 5: 17401. PMID 26620632 DOI: 10.1038/Srep17401 |
0.358 |
|
| 2013 |
Thoreen CC. Many roads from mTOR to eIF4F. Biochemical Society Transactions. 41: 913-6. PMID 23863155 DOI: 10.1042/BST20130082 |
0.345 |
|
| 2013 |
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702 |
0.687 |
|
| 2012 |
Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 485: 109-13. PMID 22552098 DOI: 10.1038/Nature11083 |
0.533 |
|
| 2012 |
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. The Journal of Biological Chemistry. 287: 9742-52. PMID 22223645 DOI: 10.1074/Jbc.M111.304485 |
0.701 |
|
| 2012 |
Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, Gray NS. Development of ATP-competitive mTOR inhibitors. Methods in Molecular Biology (Clifton, N.J.). 821: 447-60. PMID 22125084 DOI: 10.1007/978-1-61779-430-8_29 |
0.701 |
|
| 2011 |
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Choi HG, Waller DL, Sim T, Sabatini DM, Gray NS. Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. Bioorganic & Medicinal Chemistry Letters. 21: 4036-40. PMID 21621413 DOI: 10.1016/J.Bmcl.2011.04.129 |
0.639 |
|
| 2011 |
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. Journal of Medicinal Chemistry. 54: 1473-80. PMID 21322566 DOI: 10.1021/Jm101520V |
0.73 |
|
| 2011 |
Lindquist RA, Ottina KA, Wheeler DB, Hsu PP, Thoreen CC, Guertin DA, Ali SM, Sengupta S, Shaul YD, Lamprecht MR, Madden KL, Papallo AR, Jones TR, Sabatini DM, Carpenter AE. Genome-scale RNAi on living-cell microarrays identifies novel regulators of Drosophila melanogaster TORC1-S6K pathway signaling. Genome Research. 21: 433-46. PMID 21239477 DOI: 10.1101/Gr.111492.110 |
0.341 |
|
| 2010 |
Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. Journal of Medicinal Chemistry. 53: 7146-55. PMID 20860370 DOI: 10.1021/Jm101144F |
0.77 |
|
| 2009 |
Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today. Therapeutic Strategies. 6: 47-55. PMID 20622997 DOI: 10.1016/J.Ddstr.2009.12.001 |
0.725 |
|
| 2009 |
Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 137: 873-86. PMID 19446321 DOI: 10.1016/J.Cell.2009.03.046 |
0.586 |
|
| 2009 |
Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy. 5: 725-6. PMID 19395872 DOI: 10.4161/auto.5.5.8504 |
0.575 |
|
| 2009 |
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of Biological Chemistry. 284: 8023-32. PMID 19150980 DOI: 10.1074/Jbc.M900301200 |
0.756 |
|
| 2007 |
Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular Cell. 25: 903-15. PMID 17386266 DOI: 10.1016/j.molcel.2007.03.003 |
0.449 |
|
| 2006 |
Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Developmental Cell. 11: 859-71. PMID 17141160 DOI: 10.1016/J.Devcel.2006.10.007 |
0.402 |
|
| 2006 |
Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Current Biology : Cb. 16: 1865-70. PMID 16919458 DOI: 10.1016/j.cub.2006.08.001 |
0.528 |
|
| Show low-probability matches. |